Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin interaction study with ACT-246475 in healthy volunteers
NL-OMON46064Active, not recruiting
- Sponsor
- Idorsia
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of selatogrel and rifampicin in myocardial infarction (MI) (2 arms), sponsored by Idorsia. Primary endpoint: Pharmacokinetic parameters of ACT-246475. Started Jan 2019; status: active, not recruiting.
02
Drugs
selatogrelrifampicin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON46064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46064.